课题基金 / 基金详情

FGF-SAP AS AN ANTI-TUMOR AGENT--DESIGN FOR HUMAN STUDIES

FGF-SAP AS AN ANTI-TUMOR AGENT--DESIGN FOR HUMAN STUDIES
FGF-SAP 作为抗肿瘤剂——为人类研究而设计
批准号:
3493486
负责人:
BARBARA A SOSNOWSKI
金额:
$4.65万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-07-15 至 1994-03-31

项目摘要

项目成果

BARBARA A SOSNOWSKI的其他基金

相关文献

中文摘要
翻译
碱性成纤维细胞生长因子是一种自分泌生长因子 大量的肿瘤细胞。成纤维细胞生长因子-SAP(成纤维细胞生长因子和皂苷的化学结合物,以及 抑制蛋白质合成的酶)抑制黑色素瘤和卡波西氏病 肉瘤细胞在培养中生长,在肿瘤动物模型中也是活跃的。 在目前的形式下,成纤维细胞生长因子-SAP的化学结合物是一种高度 分子水平上的非均相混合物。因此,它不会放贷 符合临床所需的严格的化学特征 评价其在治疗成纤维细胞生长因子受体中的潜在应用 依赖性、增殖性疾病。出于这个原因,我们建议申请 利用重组DNA技术产生同源产物。具体的 目标是:L)设计和合成各种形式的成纤维细胞生长因子,保留所有 生长因子的有丝分裂活性,但只有一个活性部位 其与SAP的偶联,2)制备均一制剂 衍生的SAP,使其仅有一个反应位点可与 3)制备均一的化学偶联的成纤维细胞生长因子-SAP 这些新的起始材料。这项提案在以下方面提出了重大改进 一种治疗肿瘤的创新技术:直接靶向肿瘤 生长因子通过它们的受体。
英文摘要
Basic fibroblast growth factor (FGF) is an autocrine growth factor for numerous tumor cells. FGF-SAP (a chemical conjugate of FGF and saporin, an enzyme that inhibits protein synthesis) inhibits melanoma and Kaposi's sarcoma cell growth in culture and is also active in tumor animal models. In its current form, the chemical conjugate of FGF-SAP is a highly heterogeneous mixture at the molecular level. Thus, it does not lend itself to the rigorous chemical characterization required for clinical evaluation of its potential application in the treatment of FGF receptor- dependent, proliferative disease. For this reason, we propose to apply recombinant DNA technology to generate a homogeneous product. The specific aims are to: l) design and synthesize forms of FGF that retain all of the growth factor's mitogenic activity, but have only one reactive site for its conjugation to SAP, 2) prepare a homogeneous preparation of derivatized SAP, giving it only one reactive site for its conjugation to FGF, and 3) produce a homogeneous chemical conjugate FGF-SAP by using these new starting materials. This proposal presents major improvements in an innovative technology for tumOr treatment: direct tumor targeting by growth factors through their receptors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Gene Therapy for Therapeutic Angiogenesis
  • 批准号:
    6952830
  • 项目类别:
  • 资助金额:
    $101.39万
  • 财政年份:
    2004
  • 负责人:
    BARBARA A SOSNOWSKI
  • 依托单位:
Gene Therapy for Therapeutic Angiogenesis
  • 批准号:
    7144579
  • 项目类别:
  • 资助金额:
    $101.42万
  • 财政年份:
    2004
  • 负责人:
    BARBARA A SOSNOWSKI
  • 依托单位:
TARGETING OF DNA ENCODING RIBOSOMAL INHIBITOR PROTEIN
  • 批准号:
    2012617
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    1997
  • 负责人:
    BARBARA A SOSNOWSKI
  • 依托单位:
DEVELOPMENT OF AN ANTICANCER DRUG USING ERBB-2 LIGAND-S
  • 批准号:
    2105938
  • 项目类别:
  • 资助金额:
    $6.88万
  • 财政年份:
    1994
  • 负责人:
    BARBARA A SOSNOWSKI
  • 依托单位: